Poliomyelitis - Pipeline Review, H1 2017

Market: Pharmaceuticals and Healthcare

Global, 69 pages report, published by Global Markets Direct

Keywords : Poliomyelitis Therapeutic Products under Development, Key Players in Poliomyelitis Therapeutics, Poliomyelitis Pipeline Overview, Poliomyelitis Pipeline, Poliomyelitis Pipeline Assessment

Report ThumbnailJune-2017
Poliomyelitis - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Poliomyelitis - Pipeline Review, H1 2017, provides an overview of the Poliomyelitis (Infectious Disease) pipeline landscape.

Polio is a highly infectious disease caused by a virus. It invades the nervous system, and causes total paralysis in a matter of hours. Symptoms include fever, fatigue, headache, vomiting, stiffness in the neck and pain in the limbs. Preventive measures such as the use of vaccines are effective for polio.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Poliomyelitis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Poliomyelitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Poliomyelitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Poliomyelitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 7, 4, 3, 4 and 5 respectively. Similarly, the Universities portfolio in Phase III, Phase II and Discovery stages comprises 1, 2 and 1 molecules, respectively.

Poliomyelitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Poliomyelitis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Poliomyelitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Poliomyelitis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Poliomyelitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Poliomyelitis (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Poliomyelitis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Poliomyelitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Poliomyelitis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
  • List of Tables
  • Number of Products under Development for Poliomyelitis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Poliomyelitis - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2017
  • Poliomyelitis - Pipeline by Bharat Biotech International Ltd, H1 2017
  • Poliomyelitis - Pipeline by Biological E Ltd, H1 2017
  • Poliomyelitis - Pipeline by Biological Mimetics Inc, H1 2017
  • Poliomyelitis - Pipeline by Boryung Pharmaceutical Co Ltd, H1 2017
  • Poliomyelitis - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
  • Poliomyelitis - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Poliomyelitis - Pipeline by Grifols SA, H1 2017
  • Poliomyelitis - Pipeline by Johnson & Johnson, H1 2017
  • Poliomyelitis - Pipeline by Kaketsuken KK, H1 2017
  • Poliomyelitis - Pipeline by LG Chem, Ltd., H1 2017
  • Poliomyelitis - Pipeline by Nanolek, H1 2017
  • Poliomyelitis - Pipeline by Panacea Biotec Ltd, H1 2017
  • Poliomyelitis - Pipeline by Sanofi, H1 2017
  • Poliomyelitis - Pipeline by Sanofi Pasteur SA, H1 2017
  • Poliomyelitis - Pipeline by Sentinext Therapeutics Sdn Bhd, H1 2017
  • Poliomyelitis - Pipeline by Shantha Biotechnics Pvt Ltd, H1 2017
  • Poliomyelitis - Pipeline by Taiga Biotechnologies Inc, H1 2017
  • Poliomyelitis - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
  • Poliomyelitis - Dormant Projects, H1 2017
  • Poliomyelitis - Discontinued Products, H1 2017
  • Table of Contents
  • List of Tables
  • List of Figures
  • Introduction
  • Global Markets Direct Report Coverage
  • Poliomyelitis - Overview
  • Poliomyelitis - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Poliomyelitis - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Poliomyelitis - Companies Involved in Therapeutics Development
  • Beijing Minhai Biotechnology Co Ltd
  • Bharat Biotech International Ltd
  • Biological E Ltd
  • Biological Mimetics Inc
  • Boryung Pharmaceutical Co Ltd
  • Daiichi Sankyo Company Ltd
  • GlaxoSmithKline Plc
  • Grifols SA
  • Johnson & Johnson
  • Kaketsuken KK
  • LG Chem, Ltd.
  • Nanolek
  • Panacea Biotec Ltd
  • Sanofi
  • Sanofi Pasteur SA
  • Sentinext Therapeutics Sdn Bhd
  • Shantha Biotechnics Pvt Ltd
  • Taiga Biotechnologies Inc
  • Takeda Pharmaceutical Company Ltd
  • Poliomyelitis - Drug Profiles
  • (diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (diphtheria + tetanus + pertussis (acellular) + poliomyelitis + haemophilus influenzae [serotype B]) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BK-1310 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BVN-002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • DTaP-IPV-HB-PRPT - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • immune globulin (human) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ImmunoRx - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • IPVGVI-3000 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • JNJ-2348 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • KD-370 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LBVC - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LBVD - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • polio (virus like particle, bivalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • polio [serotype sabin 1, 3] (bivalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • polio [strain Sabin] vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • polio vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • polio vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • polio vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • polio vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • poliomyelitis vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • poliomyelitis vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • poliomyelitis vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TAK-195 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VN-0105 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Poliomyelitis - Dormant Projects
  • Poliomyelitis - Discontinued Products
  • Poliomyelitis - Product Development Milestones
  • Featured News & Press Releases
  • Dec 10, 2015: Sinovac Obtains Clinical Trial Approval for Sabin-IPV Candidate
  • May 11, 2011: Sanofi Pasteur Launches Pentaxim In China
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

Please select a license type

Share

Related Products

Global Markets DirectPoliomyelitis - Pipeline Review, H1 2017Product ThumbnailPoliomyelitis - Pipeline Review, H1 2017, Industry ReportProduct #: 829042
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved